Navigation Links
Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy

by a novel mechanism of action and may exert a neuroprotective effect in multiple areas of the central nervous system. Dimebon appears to block a new target that involves mitochondrial pores, which are believed to play a role in the cell death that is associated with neurodegenerative diseases and the aging process.

Medivation is currently evaluating Dimebon in both Alzheimer's and Huntington's diseases. The Company expects to enter global Phase 3 studies of Dimebon in Alzheimer's disease in 2008 and, assuming positive data, to submit marketing applications in the U.S. and Europe in 2010 for this indication. In Huntington's disease, the Company is currently evaluating Dimebon in a Phase 1-2a clinical trial in collaboration with the Huntington Study Group.

About Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs - Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the anticipated timing of clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
2. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
3. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces Presentation of Full Top-Line Data From Dimebon Six-Month Trial at Major International Alzheimers Disease Conference
5. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
6. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
7. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
8. EPIX Pharmaceuticals Announces Statistically Significant Results in Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate
9. Telik Reports Positive Data Demonstrating Synergy in Combination and Highly Statistically Significant Effect of Telcyta as Maintenance Therapy in First-Line Non-Small Cell Lung Cancer
10. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
11. Repros Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
Post Your Comments:
(Date:6/18/2013)... ANDOVER, Mass. , June 18, 2013 ... announced the company was named Overall Performance Leader in ... Medical Equipment & Infrastructure report. Philips also received Best ... of its imaging products: Ingenuity Core 128 Computed ... iE33 ultrasound and PageWriter TC70 cardiograph. The annual Best ...
(Date:6/18/2013)... , June 18, 2013 Unilife Corporation ("Unilife" ... designer, developer and manufacturer of injectable drug delivery systems, ... at www.unilife.com . The new site includes additional ... to occur on a regular basis. Mr. ... "As an emerging global leader for injectable drug delivery ...
(Date:6/18/2013)... , June 18, 2013  Women are frequently the ... unfortunately they often do not give the same priority ... kept information from their doctor because they were too ... to a recent survey conducted by Allergan and endorsed ... to bringing education, funding and research to the field ...
Breaking Medicine Technology:Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS 2Unilife Launches New Corporate Website 2New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 2New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 3New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 4New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 5New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 6New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 7New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 8New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 9
... 19 Curemark LLC, ( www.curemark.com ), a ... neurological diseases, announced that the company has begun enrolling patients ... at three additional clinical trial sites. The sites are ... Pennsylvania State University,s Pediatric Clinical Research Office at Hershey Medical ...
... , WASHINGTON, Nov. 19 A recent Reuters ... companies don,t expect an industry increase as a result ... , While 39 million additional Americans may begin receiving health ... would "depend primarily on the access" extended to the new ...
Cached Medicine Technology:Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites 2Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites 3
(Date:6/18/2013)... Palo Alto has taken yet another step ... with its recent major long-term solar power commitment. , ... electric power purchase agreements , which together will result in ... photovoltaic electric power per year, which is the equivalent of ... enough power to supply all 65,000+ Palo Alto residents---and then ...
(Date:6/18/2013)... 2013 Seven-year-old Riley Salz of Encino, ... He receives 40 hours a week of applied behavior ... the Center for Autism and Related Disorders (CARD). Riley ... and has experienced remarkable progress, including learning to speak, ... Riley’s personal journey through autism is now featured in ...
(Date:6/18/2013)... Hospitals Case Medical Center clinical researchers have launched ... which will evaluate the ability of a patient,s ... end stage peripheral arterial disease (PAD). , ... Surgery at University Hospitals Case Medical Center,s Harrington ... at Case Western Reserve University School of Medicine, ...
(Date:6/18/2013)... 18, 2013 More than 1.1 million people ... HIV/AIDS, according to the Centers for Disease Control and Prevention ... infected. In support of National HIV Testing Day on June ... Insurance (SSDI) representation, the CDC and other organizations are ... The CDC reports about 50,000 new HIV infections each year. ...
(Date:6/18/2013)... myCNAjobs announces the addition of new resources to ... to the Caregiver Resources Center. , As more caregivers ... baby boomers each day, the need for caregiver ... has never been greater. myCNAjobs, the fastest growing ... the first-ever free resource center for caregivers seeking professional ...
Breaking Medicine News(10 mins):Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 3Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:myCNAjobs Adds New Resources to Growing Caregiver Career Center 2
... FAIRFAX, Va., Sept. 25 The American Society,for ... version of,its brochure Radiation Therapy for Gynecologic Cancers. ... useful information on the,different types of radiation therapy ... on the potential side effects and how to ...
... Australia have shown that positron emission tomography (PET) ... useful than mammography and ultrasound in predicting a ... patients ultimate likelihood of survival. , In research ... (ECCO 14) in Barcelona, Dr Vinod Ganju reported ...
... new song has helped scientists open a new avenue of ... there is currently no cure or even a treatment to ... in the Journal of Clinical Investigation, scientists at the University ... someday be used to treat the disease. The team used ...
... found that the breast cancer susceptibility gene, BRCA1, plays a ... can it be used to predict outcome for patients with ... tool in choosing the best therapy for them. , Dr ... 14) in Barcelona, that analysis of the expression of five ...
... gliomas (BSGs) are rare but can be very difficult ... survival rates. However, a team of Spanish researchers have ... (I/C) produced rapid clinical responses and shrank the tumours ... enrolled in a clinical trial. , Dr Jaume Mora ...
... Researchers in The Netherlands have developed a method of ... likely to have their disease recur after surgery and ... chemotherapy. , Led by Professor Rob Tollenaar at Leiden ... at The Netherlands Cancer Institute, they have analysed for ...
Cached Medicine News:Health News:Updated Brochure on Gynecologic Cancer Treatments Now Available 2Health News:PET scans can accurately detect a breast tumor's response to chemotherapy 2Health News:PET scans can accurately detect a breast tumor's response to chemotherapy 3Health News:Stem cells show promise for treating Huntington's disease 2Health News:Stem cells show promise for treating Huntington's disease 3Health News:Stem cells show promise for treating Huntington's disease 4Health News:Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer 2Health News:Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer 3Health News:New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas 2Health News:Molecular profiling can accurately predict survival in colon cancer patients 2Health News:Molecular profiling can accurately predict survival in colon cancer patients 3
... The Clariflex® Intraocular Lens is indicated ... years of age or older in whom ... IOL is a third-generation IOL design made ... is designed both to reduce internal reflections ...
... Lenses: The Bausch & Lomb PMMA Posterior Chamber ... primary implantation for the visual correction of aphakia ... where a cataractous lens has been removed by ... be placed in the ciliary sulcus or capsular ...
... USIOL lenses are manufactured using ... processes. Perspex CQ UV PMMA ... multi-piece and single piece lenses. ... in both nonphaco and phaco ...
... II is a sterile nonpyrogenic, transparent viscoelastic ... II contains 12 mg/ml of high molecular ... hyaluronate dissolved in physiological saline. In the ... is 105,000 cps (105 Pa s) at ...
Medicine Products: